Get informed when a big investor buys or sells
+ FollowUndervalued by 86.3% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $6.29 Trillion |
|---|---|
| Enterprise Value | $6.07 Trillion |
| Annual dividend | $0.43 |
| Dividend yield | 1.41% |
| Earnings per Share | $359.19 |
| Beta | -0.05 |
| Outstanding Shares | 0 |
| P/E Ratio | 22.53 |
|---|---|
| PEG | -143.7 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2.23 |
| Enterprise Value to EBIT | 12.5 |
| Enterprise Value to Net Income | 15 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.08 |
No data
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Holdings and activity of institutional investors.
| Ownership % | 0.30%▼ 0.01% |
|---|---|
| Total Invested | $105.02M▼ 5.90% |
| Investors Holding | 100% |
Otsuka Holdings Co., Ltd. engages in the pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. It develops pharmaceutical products in the fields of psychiatry, neurology, oncology, cardiovascular and renal s...